ASCO 2017: BRCA Mutated Breast Cancer and PARP Inhibitors: Current and Future

Speaker: Nicholas Turner

Nicholas Turner highlights the importance of the practice changing results presented at ASCO 2017 on PARP inhibition in patients with BRCA mutated metastatic breast cancer.

Nicholas Turner highlights the importance of the practice changing results presented at ASCO 2017 on PARP inhibition in patients with BRCA mutated metastatic breast cancer.

Abstracts as referenced in the ASCO 2017 programme

  • LBA4: OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). 
  • 1007: Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 Mutations (ABRAZO).